Aribio and AribioLab to Participate in BIO USA... Pursuing Partnerships in CNS and Vaccine Platforms
Introduction of Follow-up Pipeline and Electroceutical Technologies Based on AR1001
Discussion on Commercialization of AribioLab’s Immune Adjuvant Platform ‘Lipo-pam’
Aribio and AribioLab announced on June 15 that they will jointly participate in the 'BIO International Convention 2026 (BIO USA)' to be held in San Diego, United States, starting June 22.
At this event, the two companies plan to introduce their Alzheimer’s disease treatment candidate AR1001, as well as subsequent neuroscience pipelines, electroceutical technologies, and vaccine and immunology platform technologies. They will also seek to pursue global partnership opportunities.
Based on its experience with the global Phase 3 clinical development of AR1001, Aribio will explore opportunities for collaboration in its subsequent central nervous system (CNS) pipeline and the electroceutical field. The follow-up candidate AR1005 is under development as a treatment for dementia with Lewy bodies (DLB), and a Phase 2 clinical trial is currently underway at Severance Hospital.
The vibration acoustic stimulation (tVAS)-based electroceutical GVD-01 has completed exploratory clinical trials in patients with early-stage Alzheimer’s disease, and the company is seeking to expand its indications to include mild cognitive impairment (MCI), neuropsychiatric symptoms after stroke, and sleep disorders.
AribioLab is working to commercialize vaccine and immunology platforms based on its immune adjuvant platform 'Lipo-pam™'. The company is currently conducting a Phase 2 clinical trial for a shingles vaccine, and during this BIO USA, it plans to discuss potential joint development and licensing collaborations based on Lipo-pam.
Hot Picks Today
"We'll Pay 100% of Bonuses in Stock, Not Cash"...Employees Voting at This Company
- "Losing Jobs and Selling Bean Sprouts: Why They Left a Job Earning 6.76 Million Won per Month"
- "How Much Further Can It Fall?" Balances Fluctuate as KOSPI Drops 5% After Two Days of Gains
- Cardiac Arrests Surge in 40-Degree Heatwave, Hospitals Overwhelmed... Paris Issues Emergency "No Drinking" Ban
- "‘Hong Myungbo Banned from Entry’ Posted on Convenience Store Door... Headquarters Investigating Store Location"
A representative from Aribio stated, "This BIO USA will serve as an opportunity to expand global collaboration for follow-up pipelines and platform technologies, building on our experience with AR1001 development," adding, "We plan to pursue partnerships in the fields of CNS drugs, electroceuticals, and vaccine and immunology platforms."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
